SEARCH:   Advanced

Blood, 1 October 2007, Vol. 110, No. 7, pp. 2659-2666. Prepublished online as a Blood First Edition Paper on July 3, 2007; DOI 10.1182/blood-2007-03-083048. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-03-083048v1 110/7/2659    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by van Rhenen, A. Articles by Jan Schuurhuis, G. Search for Related Content PubMed PubMed Citation Articles by van Rhenen, A. Articles by Jan Schuurhuis, G. Related Collections Hematopoiesis and Stem Cells Neoplasia Stem Cells in Hematology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells Anna van Rhenen1, Guus A. M. S. van Dongen2, Angèle Kelder1, Elwin J. Rombouts3, Nicole Feller1, Bijan Moshaver1, Marijke Stigter-van Walsum2, Sonja Zweegman1, Gert J. Ossenkoppele1, and Gerrit Jan Schuurhuis1 1 Department of Hematology and 2 Department of Otolaryngology, VU [Vrije Universiteit] University Medical Center, Amsterdam; 3 Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands In CD34+ acute myeloid leukemia (AML), the malignant stem cells reside in the CD38– compartment. We have shown before that the frequency of such CD34+CD38– cells at diagnosis correlates with minimal residual disease (MRD) frequency after chemotherapy and with survival. Specific targeting of CD34+CD38– cells might thus offer therapeutic options. Previously, we found that C-type lectin-like molecule-1 (CLL-1) has high expression on the whole blast compartment in the majority of AML cases. We now show that CLL-1 expression is also present on the CD34+CD38– stem- cell compartment in AML (77/89 patients). The CD34+CLL-1+ population, containing the CD34+CD38–CLL-1+ cells, does engraft in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with outgrowth to CLL-1+ blasts. CLL-1 expression was not different between diagnosis and relapse (n = 9). In remission, both CLL-1– normal and CLL-1+ malignant CD34+CD38– cells were present. A high CLL-1+ fraction was associated with quick relapse. CLL-1 expression is completely absent both on CD34+CD38– cells in normal (n = 11) and in regenerating bone marrow controls (n = 6). This AML stem-cell specificity of the anti-CLL-1 antibody under all conditions of disease and the leukemia-initiating properties of CD34+CLL-1+ cells indicate that anti–CLL-1 antibody enables both AML-specific stem-cell detection and possibly antigen-targeting in future. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. Moshaver, A. van Rhenen, A. Kelder, M. van der Pol, M. Terwijn, C. Bachas, A. H. Westra, G. J. Ossenkoppele, S. Zweegman, and G. J. Schuurhuis Identification of a Small Subpopulation of Candidate Leukemia-Initiating Cells in the Side Population of Patients with Acute Myeloid Leukemia Stem Cells, December 1, 2008; 26(12): 3059 - 3067. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020